陈城医师:该研究尚未获得伦理委员会批准,请于批准后再开始纳入参试者,并与我们联系上传批件。 基于人工智能踝关节炎手术规划和个性化截骨导板及矫形融合体的临床研究

注册号:

Registration number:

ChiCTR2000035728 

最近更新日期:

Date of Last Refreshed on:

2020-08-16 22:26:31 

注册时间:

Date of Registration:

2020-08-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

陈城医师:该研究尚未获得伦理委员会批准,请于批准后再开始纳入参试者,并与我们联系上传批件。 基于人工智能踝关节炎手术规划和个性化截骨导板及矫形融合体的临床研究

Public title:

The Clinical Control Study on surgical planning and personalized osteotomy guide plate and orthopedic fusion body based on artificial intelligence for ankle arthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于人工智能踝关节炎手术规划和个性化截骨导板及矫形融合体的临床研究

Scientific title:

The Clinical Control Study on surgical planning and personalized osteotomy guide plate and orthopedic fusion body based on artificial intelligence for ankle arthritis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈城 

研究负责人:

施忠民 

Applicant:

Chencheng 

Study leader:

ShiZhongmin 

申请注册联系人电话:

Applicant telephone:

+86 19121708310

研究负责人电话:

Study leader's
telephone:

+86 18930177323

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

18930281830@163.com

研究负责人电子邮件:

Study leader's E-mail:

18930177323@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市宜山路600号

研究负责人通讯地址:

上海市徐汇区宜山路600号

Applicant address:

600 Yishan Road, Xuhui District, Shanghai, China

Study leader's address:

600 Yishan Road, Xuhui District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第六人民医院骨科

Applicant's institution:

Orthopaedics Department, Shanghai Sixth People's Hospital

研究负责人所在单位:

上海市第六人民医院骨科

Affiliation of the Leader:

Orthopaedics Department, Shanghai Sixth People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第六人民医院

Primary sponsor:

Shanghai Sixth People's Hospital

研究实施负责(组长)单位地址:

上海市徐汇区宜山路600号

Primary sponsor's address:

600 Yishan Road, Xuhui District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

shanghai

City:

单位(医院):

上海市第六人民医院

具体地址:

徐汇区宜山路600号

Institution
hospital:

Shanghai Sixth People's Hospital

Address:

600 Yishan Road, Xuhui District, Shanghai, China

经费或物资来源:

《促进市级医院临床技能与临床创新三年行动计划(2020-2022)》重大临床研究项目

Source(s) of funding:

Major clinical research projects of 3-year plan for promoting clinical skills and clinical innovation in municipal hospitals

研究疾病:

踝关节骨折畸形愈合  

Target disease:

Malunion of ankle fracture

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究课题拟通过人工智能手术规划和手术导板设计方案和有限元分析方法,对踝关节骨折畸形愈合病例进行金属3D打印下肢矫形融合体植入辅助截骨进行临床研究,来了解具有其临床性能及疗效。  

Objectives of Study:

In this study, through the artificial intelligence operation planning and surgical guide plate design scheme and finite element analysis method, the metal 3D printing lower limb orthopedic fusion body implantation assisted osteotomy was carried out in the ankle fracture malunion cases to understand its clinical performance and therapeutic effect.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1)终末期踝关节炎者;
2)精神疾病患者或患者精神上无能力或者不能理解参与研究的要求;
3)受试者呈免疫抑制状态,患有自身免疫疾病或者免疫抑制障碍;
4)长期酗酒、滥用药物等患者;
5)研究者认为不适合入选患者。

Exclusion criteria:

1. End-stage ankle arthritis patients;
2. Mental incapacity or inability to understand the requirements for participation in the study in patients or patients with mental illness;
3. Subjects are immunosuppressive, suffering from autoimmune diseases or immunosuppressive disorders;
4. Chronic alcoholism, drug abuse and other patients;
5. The researchers didn't think it was appropriate for the patients to be included.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 2022-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 2021-12-30 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

20

Group:

control group

Sample size:

干预措施:

普通的截骨导板进行矫形

干预措施代码:

Intervention:

orthopedic treatment with common osteotomy guide plate

Intervention code:

组别:

试验组

样本量:

20

Group:

experimental group

Sample size:

干预措施:

通过人工智能手术规划和手术导板设计方案和有限元分析方法,进行金属3D打印下肢矫形融合体植入辅助截骨

干预措施代码:

Intervention:

Through artificial intelligence surgery planning, surgical guide plate design and finite element analysis method, clinical trial scheme formulated, and metal 3D printing lower limb orthopedic fusion implanted to assist osteotomy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

徐汇区 

Country:

China

Province:

Shanghai

City:

Xuhui District

单位(医院):

上海市第六人民医院 

单位级别:

三甲 

Institution
hospital:

Shanghai Sixth People's Hospita

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

踝关节活动度

指标类型:

主要指标

Outcome:

ankle range

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛视觉评分

指标类型:

主要指标

Outcome:

VAS score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SF-36评分

指标类型:

主要指标

Outcome:

SF-36 score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

美国足踝外科评分

指标类型:

主要指标

Outcome:

AOFAS score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

踝关节核磁共振

指标类型:

主要指标

Outcome:

ankle MRI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 50 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

简单随机化分组。(1)将60个实验单位从1~60编号。(2)从随机数字表中任意一个数开始,沿同一方向顺序获取每个实验单位一个随机数字;(3)随机数除以组数求余数。若整除,则余数为组数。(4)按余数分组。(5)调整,假如共有n例待调整,需要从中抽取1例,便续抄一个随机数,除以n后得到的余数作为所抽实验单位的序号。

Randomization Procedure (please state who generates the random number sequence and by what method):

block randomization by the random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

开放

Blinding:

open-label

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publication of papers

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例数据采集和电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record and Electronic data capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-08-16 22:17:11